UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2021
Commission File Number: 001-39446
(Exact Name of Registrant as Specified in Its Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | ⌧ |
| Form 40-F | ☐ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes | ☐ |
| No | ⌧ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes | ☐ | No | ⌧ |
This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the “SEC”) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac’s financial results and business updates as of September 30, 2021 and December 31, 2020 and for the nine month periods ended September 30, 2021 and 2020; (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of September 30, 2021 and December 31, 2020 and for the nine month periods ended September 30, 2021 and 2020; (iii) furnishing, as Exhibit 99.3 to this Form 6-K, the second amendment to and restatement of the Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, which was entered into on September 29, 2021; and (iv) furnishing, as Exhibit 99.4 to this Form 6-K, the amendment to and restatement of the COVID Collaboration and License Agreement by and between Curevac AG and Glaxosmithkline Biological SA, which was entered into on September 29, 2021.
The information included in this Form 6-K (including Exhibits 99.1, 99.2, 99.3 and 99.4) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).
EXHIBIT INDEX
EXHIBIT NO. |
| DESCRIPTION |
99.1 | ||
99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | |
99.3 | ||
99.4 |